10x Genomics Rises 3.4% as Raised Outlook and Analyst Reset Support Shares

10x Genomics (TXG) is up 3.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be continued follow-through from the company’s stronger August earnings update, which included a higher full-year revenue outlook and upbeat commentary on early demand for Atera. A more recent analyst price-target increase may also be helping sentiment, although there does not appear to be one obvious new company-specific announcement tied directly to today’s move.

Details:

In its second-quarter 2026 earnings release, 10x Genomics posted revenue of $151.0 million and said product and services revenue rose year over year after adjusting for non-recurring patent-settlement revenue.

The company raised its full-year 2026 revenue guidance to a range of $610 million to $630 million, up from its prior range of $600 million to $625 million.

Management highlighted strong early order flow for Atera, and the company also announced the acquisition of Proteintech Genomics to add protein-detection capabilities to its single-cell and spatial platforms.

On September 9, UBS maintained a Neutral rating on TXG and lifted its price target to $68 from $20, a sizable reset that may still be influencing trading sentiment.

Sources:

SEC, 10x Genomics Investor Relations, Google Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TXG Insider Trading Activity

$TXG insiders have traded $TXG stock on the open market 30 times in the past 6 months. Of those trades, 0 have been purchases and 30 have been sales.

Here’s a breakdown of recent trading of $TXG stock by insiders over the last 6 months:

ADAM TAICH (Chief Financial Officer) has made 0 purchases and 5 sales selling 78,652 shares for an estimated $4,446,341.
SERGE SAXONOV (Chief Executive Officer) has made 0 purchases and 12 sales selling 97,924 shares for an estimated $3,799,396.
JOHN R STUELPNAGEL has made 0 purchases and 5 sales selling 40,000 shares for an estimated $2,390,127.
BENJAMIN J. HINDSON (See Remarks) has made 0 purchases and 2 sales selling 25,413 shares for an estimated $1,154,259.
SARAH A. TEICHMANN has made 0 purchases and 2 sales selling 7,551 shares for an estimated $432,278.
SHEHNAAZ SULIMAN has made 0 purchases and 4 sales selling 7,930 shares for an estimated $327,234.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$TXG Hedge Fund Activity

We have seen 200 institutional investors add shares of $TXG stock to their portfolio, and 191 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ added 4,375,792 shares (+2681.0%) to their portfolio in Q2 2026, for an estimated $167,767,865
MILLENNIUM MANAGEMENT LLC removed 1,951,581 shares (-94.4%) from their portfolio in Q2 2026, for an estimated $74,823,615
POINT72 ASSET MANAGEMENT, L.P. added 1,852,776 shares (+inf%) to their portfolio in Q2 2026, for an estimated $71,035,431
ARK INVESTMENT MANAGEMENT LLC removed 1,714,260 shares (-14.6%) from their portfolio in Q2 2026, for an estimated $65,724,728
WELLINGTON MANAGEMENT GROUP LLP removed 1,448,765 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $30,757,280
CASDIN CAPITAL, LLC removed 1,225,000 shares (-53.8%) from their portfolio in Q2 2026, for an estimated $46,966,500
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,087,150 shares (+inf%) to their portfolio in Q2 2026, for an estimated $41,681,331

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TXG Government Contracts

We have seen $4,821,209 of award payments to $TXG over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$TXG Analyst Ratings

Wall Street analysts have issued reports on $TXG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

William Blair issued a "Outperform" rating on 03/31/2026

To track analyst ratings and price targets for $TXG, check out Quiver Quantitative's $TXG forecast page.

$TXG Price Targets

Multiple analysts have issued price targets for $TXG recently. We have seen 8 analysts offer price targets for $TXG in the last 6 months, with a median target of $38.5.

Here are some recent targets:

Tejas Savant from Morgan Stanley set a target price of $37.0 on 07/09/2026
Patrick Donnelly from Citigroup set a target price of $45.0 on 07/08/2026
Eric Winmill from Scotiabank set a target price of $100.0 on 07/08/2026
David Westenberg from Piper Sandler set a target price of $42.0 on 07/01/2026
Luke Sergott from Barclays set a target price of $40.0 on 06/24/2026
Casey Woodring from JP Morgan set a target price of $20.0 on 05/12/2026
Kyle Mikson from Canaccord Genuity set a target price of $32.0 on 04/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.